Exploiting natural variation to discover tools to increase crop plant yield. This project aims to identify the specific biochemical and underlying molecular modifications that contributed to the evolution of the C4 pathway by studying C3, C4 and C3-C4 intermediate Flaveria species. Most land plants use C3 or C4 photosynthesis to assimilate CO2. Plants using the C4 pathway evolved from C3 ancestors in multiple plant lineages, and show higher rates of photosynthesis and conversion of solar radiati ....Exploiting natural variation to discover tools to increase crop plant yield. This project aims to identify the specific biochemical and underlying molecular modifications that contributed to the evolution of the C4 pathway by studying C3, C4 and C3-C4 intermediate Flaveria species. Most land plants use C3 or C4 photosynthesis to assimilate CO2. Plants using the C4 pathway evolved from C3 ancestors in multiple plant lineages, and show higher rates of photosynthesis and conversion of solar radiation to biomass in arid, high-light and saline environments, which are expanding due to global climate change. The outcomes of this project could define what is required to engineer plant varieties with increased yield and the ability to withstand effects of climate shift, and contribute to our understanding of convergent evolutionary processes.Read moreRead less
Single-cell Optical Window Imaging In CDK1-FRET Biosensor Mice To Assess Tissue Stiffness And Optimise Delivery And Therapeutic Response To Gemcitabine/Abraxane In Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$676,979.00
Summary
Inefficient drug response in solid tumour tissue is commonly a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we have mapped areas of poor drug response within distinct regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug targeting in order to improve the encouraging anti-cancer profile of the new drug combination Gemcitabine/Abraxane in pancreatic cancer.
Biosensor Imaging In Preclinical Pancreatic Cancer Targeting: Taking Cancer Targeting To New Dimensions.
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Using cutting-edge imaging technology and 3D models that mimic cancer, we can map areas of poor drug response within distinct 'stages' or regions of tumours. Here, we pinpoint and specifically target key factors limiting efficient drug response in order to improve the encouraging anti-cancer profile of new or current drugs in pancreatic cancer.
Therapeutic Targeting Of Cell Cycle Checkpoint Aberrations In Pancreatic Cancer: Personalised Medicine In Action
Funder
National Health and Medical Research Council
Funding Amount
$634,354.00
Summary
Less than 5% of people with pancreatic cancer (PC) survive 5 years, and the odds of patients beating this disease have remained unchanged for 50 years. Consequently, there is an urgent need to develop novel treatment approaches for this highly aggressive cancer. Our study aims to define novel therapeutic strategies for PC utilising specific anti-proliferative therapies and a personalised “companion biomarker” directed strategy.
Evaluation Of Molecular Mechanisms Driving Metastasis Using Integrated Intravital Imaging
Funder
National Health and Medical Research Council
Funding Amount
$885,271.00
Summary
Metastasis is the leading cause of cancer-associated death. Understanding key steps that drive the spread of cancer is critical to improve current treatment strategies. Using cutting-edge imaging technology and 3-dimensional model systems that mimic the disease, we will pinpoint key events that are susceptible to drug intervention and identify new therapeutic targets.
Targeting PI3K-regulated Small Non-coding RNAs To Restore Cardiac Function
Funder
National Health and Medical Research Council
Funding Amount
$610,204.00
Summary
Heart failure affects approximately 2.4% of the adult population and over 11% of people over 80 years old. The majority of existing therapies slow, rather than reverse heart failure progression. The primary goal of this study is to determine whether regulating novel regulatory genes can enhance cardiac function in a setting of heart failure. Ultimately, technologies that target these genes may lead to innovative pharmacotherapies in the clinical management of heart failure.
Defining The Molecular Effectors Of Gene/environment Interaction On Mouse Heart Development
Funder
National Health and Medical Research Council
Funding Amount
$749,271.00
Summary
One third of all birth defects involve the heart, and are the most common cause of infant death. Some defects are due to genetic factors, but others arise when the pregnant mother is exposed to environmental stress. We will examine how one stress (low oxygen levels) causes abnormal heart formation in the embryo, look at what causes this at a molecular level, and explore if such stress increases the risk of heart defects in families with a history of such abnormalities
This study aims to elucidate central pathways which can be manipulated to drive the storage of excess energy away from fat and instead directing it into the production of bone mass. Having identified leptin-responsive NPY neurons as important in the control of energy partitioning, we will focus on manipulating these neurons in the hypothalamus using innovative technology to alter body composition. This research has the potential to result in novel treatments for obesity and osteoporosis.
The Effects Of Estrogen-Responsive B Box Protein On Retinoid Sensitivity In Cancer And Its Significance In Development
Funder
National Health and Medical Research Council
Funding Amount
$82,421.00
Summary
Although effective, many cancer drugs often lead to side effects, especially in children. New therapies are needed that specifically target cancer cells while leaving normal cells unaffected. I am studying a novel protein (EBBP) which I believe has an important role in cancer cell growth. By studying EBBP I aim to be able to increase the effectiveness of the low toxic chemotherapy retinoic acid without increased side effects, as well as understand the functional role of EBBP in cancer cells.